CN112220914A - Medical ray protection spray containing plant exosomes - Google Patents
Medical ray protection spray containing plant exosomes Download PDFInfo
- Publication number
- CN112220914A CN112220914A CN202011053392.XA CN202011053392A CN112220914A CN 112220914 A CN112220914 A CN 112220914A CN 202011053392 A CN202011053392 A CN 202011053392A CN 112220914 A CN112220914 A CN 112220914A
- Authority
- CN
- China
- Prior art keywords
- rose
- superoxide dismutase
- dried powder
- chitosan
- purified water
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 210000001808 exosome Anatomy 0.000 title claims abstract description 120
- 239000007921 spray Substances 0.000 title claims abstract description 44
- 102000019197 Superoxide Dismutase Human genes 0.000 claims abstract description 93
- 108010012715 Superoxide dismutase Proteins 0.000 claims abstract description 93
- 241000220317 Rosa Species 0.000 claims abstract description 88
- 239000000843 powder Substances 0.000 claims abstract description 67
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 57
- 239000008213 purified water Substances 0.000 claims abstract description 53
- 241000196324 Embryophyta Species 0.000 claims abstract description 32
- 229920001661 Chitosan Polymers 0.000 claims description 68
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 claims description 56
- 239000000661 sodium alginate Substances 0.000 claims description 56
- 229940005550 sodium alginate Drugs 0.000 claims description 56
- 235000010413 sodium alginate Nutrition 0.000 claims description 56
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims description 40
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 30
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 claims description 20
- 229930003268 Vitamin C Natural products 0.000 claims description 20
- 235000019154 vitamin C Nutrition 0.000 claims description 20
- 239000011718 vitamin C Substances 0.000 claims description 20
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims description 19
- 229930195725 Mannitol Natural products 0.000 claims description 19
- 239000000594 mannitol Substances 0.000 claims description 19
- 235000010355 mannitol Nutrition 0.000 claims description 19
- CHHHXKFHOYLYRE-UHFFFAOYSA-M 2,4-Hexadienoic acid, potassium salt (1:1), (2E,4E)- Chemical compound [K+].CC=CC=CC([O-])=O CHHHXKFHOYLYRE-UHFFFAOYSA-M 0.000 claims description 17
- 239000004302 potassium sorbate Substances 0.000 claims description 17
- 229940069338 potassium sorbate Drugs 0.000 claims description 17
- 235000010241 potassium sorbate Nutrition 0.000 claims description 17
- 229940045110 chitosan Drugs 0.000 claims description 12
- ZAKOWWREFLAJOT-CEFNRUSXSA-N D-alpha-tocopherylacetate Chemical compound CC(=O)OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C ZAKOWWREFLAJOT-CEFNRUSXSA-N 0.000 claims description 10
- ZAKOWWREFLAJOT-UHFFFAOYSA-N d-alpha-Tocopheryl acetate Natural products CC(=O)OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C ZAKOWWREFLAJOT-UHFFFAOYSA-N 0.000 claims description 10
- 235000011187 glycerol Nutrition 0.000 claims description 10
- 229940042585 tocopherol acetate Drugs 0.000 claims description 10
- 239000008176 lyophilized powder Substances 0.000 claims description 9
- 229960001855 mannitol Drugs 0.000 claims description 6
- 229960005150 glycerol Drugs 0.000 claims description 3
- 241000628997 Flos Species 0.000 claims description 2
- 230000008439 repair process Effects 0.000 abstract description 18
- 210000001519 tissue Anatomy 0.000 abstract description 16
- 230000005778 DNA damage Effects 0.000 abstract description 2
- 231100000277 DNA damage Toxicity 0.000 abstract description 2
- 230000005779 cell damage Effects 0.000 abstract description 2
- 208000037887 cell injury Diseases 0.000 abstract description 2
- 210000003491 skin Anatomy 0.000 description 48
- 230000000694 effects Effects 0.000 description 34
- 230000005855 radiation Effects 0.000 description 28
- 150000003254 radicals Chemical class 0.000 description 15
- 208000027418 Wounds and injury Diseases 0.000 description 9
- 210000004027 cell Anatomy 0.000 description 9
- 238000001959 radiotherapy Methods 0.000 description 8
- 230000006378 damage Effects 0.000 description 7
- 206010052428 Wound Diseases 0.000 description 6
- 230000009286 beneficial effect Effects 0.000 description 6
- 238000010438 heat treatment Methods 0.000 description 6
- 230000003020 moisturizing effect Effects 0.000 description 6
- 230000019612 pigmentation Effects 0.000 description 6
- 238000012360 testing method Methods 0.000 description 6
- 206010061218 Inflammation Diseases 0.000 description 5
- 230000004054 inflammatory process Effects 0.000 description 5
- 230000003647 oxidation Effects 0.000 description 5
- 238000007254 oxidation reaction Methods 0.000 description 5
- 208000006934 radiodermatitis Diseases 0.000 description 5
- 201000004624 Dermatitis Diseases 0.000 description 4
- OUUQCZGPVNCOIJ-UHFFFAOYSA-M Superoxide Chemical compound [O-][O] OUUQCZGPVNCOIJ-UHFFFAOYSA-M 0.000 description 4
- 208000025865 Ulcer Diseases 0.000 description 4
- 238000010521 absorption reaction Methods 0.000 description 4
- 239000004480 active ingredient Substances 0.000 description 4
- 230000001154 acute effect Effects 0.000 description 4
- 230000003750 conditioning effect Effects 0.000 description 4
- 206010020718 hyperplasia Diseases 0.000 description 4
- 210000004877 mucosa Anatomy 0.000 description 4
- 239000012466 permeate Substances 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- 231100000241 scar Toxicity 0.000 description 4
- 230000008591 skin barrier function Effects 0.000 description 4
- 230000001225 therapeutic effect Effects 0.000 description 4
- 231100000397 ulcer Toxicity 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 3
- 206010028980 Neoplasm Diseases 0.000 description 3
- 241000700159 Rattus Species 0.000 description 3
- 230000002500 effect on skin Effects 0.000 description 3
- -1 hydroxyl free radical Chemical class 0.000 description 3
- 208000014674 injury Diseases 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- 230000002035 prolonged effect Effects 0.000 description 3
- 210000004927 skin cell Anatomy 0.000 description 3
- 238000005507 spraying Methods 0.000 description 3
- 206010002198 Anaphylactic reaction Diseases 0.000 description 2
- 206010015150 Erythema Diseases 0.000 description 2
- 239000004909 Moisturizer Substances 0.000 description 2
- 206010030113 Oedema Diseases 0.000 description 2
- 206010051246 Photodermatosis Diseases 0.000 description 2
- 206010040849 Skin fissures Diseases 0.000 description 2
- 206010040914 Skin reaction Diseases 0.000 description 2
- 102000003425 Tyrosinase Human genes 0.000 description 2
- 108060008724 Tyrosinase Proteins 0.000 description 2
- 208000003455 anaphylaxis Diseases 0.000 description 2
- 239000003242 anti bacterial agent Substances 0.000 description 2
- 229940088710 antibiotic agent Drugs 0.000 description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
- 230000037365 barrier function of the epidermis Effects 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 239000002131 composite material Substances 0.000 description 2
- 210000002808 connective tissue Anatomy 0.000 description 2
- 230000002951 depilatory effect Effects 0.000 description 2
- 230000008021 deposition Effects 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 210000002615 epidermis Anatomy 0.000 description 2
- 231100000321 erythema Toxicity 0.000 description 2
- 230000002779 inactivation Effects 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 230000001333 moisturizer Effects 0.000 description 2
- 239000005445 natural material Substances 0.000 description 2
- 210000004493 neutrocyte Anatomy 0.000 description 2
- 235000016709 nutrition Nutrition 0.000 description 2
- 229910052760 oxygen Inorganic materials 0.000 description 2
- 239000001301 oxygen Substances 0.000 description 2
- 230000008845 photoaging Effects 0.000 description 2
- 230000008832 photodamage Effects 0.000 description 2
- 239000000049 pigment Substances 0.000 description 2
- 239000002244 precipitate Substances 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 238000004321 preservation Methods 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 230000002285 radioactive effect Effects 0.000 description 2
- 230000002000 scavenging effect Effects 0.000 description 2
- 230000035945 sensitivity Effects 0.000 description 2
- 230000035483 skin reaction Effects 0.000 description 2
- 231100000430 skin reaction Toxicity 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 239000003381 stabilizer Substances 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- 230000002087 whitening effect Effects 0.000 description 2
- 230000029663 wound healing Effects 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 208000032843 Hemorrhage Diseases 0.000 description 1
- 206010028851 Necrosis Diseases 0.000 description 1
- 206010057249 Phagocytosis Diseases 0.000 description 1
- 208000019155 Radiation injury Diseases 0.000 description 1
- 206010040844 Skin exfoliation Diseases 0.000 description 1
- 208000028990 Skin injury Diseases 0.000 description 1
- 210000000683 abdominal cavity Anatomy 0.000 description 1
- 230000036783 anaphylactic response Effects 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 238000009395 breeding Methods 0.000 description 1
- 230000001488 breeding effect Effects 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000000994 depressogenic effect Effects 0.000 description 1
- 230000035618 desquamation Effects 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 230000003325 follicular Effects 0.000 description 1
- 210000000245 forearm Anatomy 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 208000014829 head and neck neoplasm Diseases 0.000 description 1
- 230000001678 irradiating effect Effects 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 229960001412 pentobarbital Drugs 0.000 description 1
- WEXRUCMBJFQVBZ-UHFFFAOYSA-N pentobarbital Chemical compound CCCC(C)C1(CC)C(=O)NC(=O)NC1=O WEXRUCMBJFQVBZ-UHFFFAOYSA-N 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 230000008782 phagocytosis Effects 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 238000003908 quality control method Methods 0.000 description 1
- 239000002516 radical scavenger Substances 0.000 description 1
- 230000004223 radioprotective effect Effects 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 239000011435 rock Substances 0.000 description 1
- 229910052979 sodium sulfide Inorganic materials 0.000 description 1
- GRVFOGOEDUUMBP-UHFFFAOYSA-N sodium sulfide (anhydrous) Chemical compound [Na+].[Na+].[S-2] GRVFOGOEDUUMBP-UHFFFAOYSA-N 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 230000035900 sweating Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 230000000451 tissue damage Effects 0.000 description 1
- 231100000827 tissue damage Toxicity 0.000 description 1
- 238000012795 verification Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/44—Oxidoreductases (1)
- A61K38/446—Superoxide dismutase (1.15)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/73—Rosaceae (Rose family), e.g. strawberry, chokeberry, blackberry, pear or firethorn
- A61K36/738—Rosa (rose)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/12—Aerosols; Foams
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/16—Emollients or protectives, e.g. against radiation
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y115/00—Oxidoreductases acting on superoxide as acceptor (1.15)
- C12Y115/01—Oxidoreductases acting on superoxide as acceptor (1.15) with NAD or NADP as acceptor (1.15.1)
- C12Y115/01001—Superoxide dismutase (1.15.1.1)
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Dermatology (AREA)
- Dispersion Chemistry (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Biochemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Molecular Biology (AREA)
- Inorganic Chemistry (AREA)
- Toxicology (AREA)
- Immunology (AREA)
- General Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Alternative & Traditional Medicine (AREA)
- Biotechnology (AREA)
- Botany (AREA)
- Medical Informatics (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
Abstract
The invention provides a medical ray protection spray containing plant exosomes, which consists of the following components: superoxide dismutase, rose exosome freeze-dried powder and purified water, wherein each 100ml of the rose exosome freeze-dried powder contains 0.05-0.1g of superoxide dismutase, 0.01-0.2g of rose exosome freeze-dried powder and the balance of purified water. The invention provides a medical ray protection spray containing plant exosomes, which can effectively remove free radicals in the deep tissue, effectively repair cell damage and DNA damage and accelerate the repair of damaged skin.
Description
Technical Field
The invention belongs to the technical field of skin injury repair, and particularly relates to a medical ray protection spray containing plant exosomes.
Background
Radiation therapy is one of the main therapeutic approaches for malignant tumors. However, in radiotherapy, the skin mucosa tissue of the irradiated part is irradiated with radiation due to the indirect effect of the medical radiation, i.e. the medical radiation ionizes water molecules in the tissue of the irradiated part to generate a large amount of toxic free radicals (such as superoxide free radical O-2, hydrated electron eaq-, hydroxyl free radical OH, etc.), and these toxic free radicals attack the tissue cells of the irradiated part, thereby causing radiation damage to the skin mucosa tissue of the irradiated part. Pajak et al report that acute radiation skin mucosa injury is an important factor affecting the therapeutic effect of tumors; if the head and neck tumor patient who carries out radiotherapy produces local skin mucosa acute radiation injury, the total course of treatment can be prolonged by up to 14 days, and the local control rate of the tumor is reduced by 13-24%. Therefore, prevention and alleviation of acute radiation-induced skin mucosal damage is important to ensure the therapeutic efficacy of tumor patients (Pajak TF, Laramor GE, Marial Va, equivalent. applied treatment day-actual quality control review in head and rock variants. int J radial Oncolobiol Phys, 1991, 20: 13-20.).
During burn, a large amount of neutrophilic leukocytes are locally accumulated on the surface of a burn wound, and the phagocytosis of the accumulated neutrophilic leukocytes on the surface of the wound generates high-concentration superoxide radical (O)-2)。O-2Can attack the surrounding normal cells, especially collagen in the tissues, so that the wound surface is difficult to heal and the burn wound surface is scarred.
Many studies have shown that SOD is a superoxide radical (O)-2) The specific high-efficiency scavenger. Therefore, SOD can be used to reduce the local radiation damage suffered by radiotherapy patients. However, because of the large molecular weight of SOD (32000Da), it is useful for eliminating O in skin mucosal tissue-2In the process, the permeability of SOD has certain limitation, on one hand, SOD can not remove free radicals in the deep tissue, on the other hand, SOD can not enter the cell to repair damaged cells and damaged DNA from the root, so that the recovery of the damaged skin needs a long time, particularly the skin with ulcer is easy to generate anaphylactic reaction by using the existing ray protection spray containing SOD, and the ulcer surface can not be healed for a long time.
On the other hand, the skin after radioactive damage is easy to generate pigmentation and scar hyperplasia, the SOD can only remove free radicals of the organism to repair tissue damage, but can not lighten pigmentation and eliminate scar hyperplasia, but because the skin after being damaged by the radiation is sensitive, the general ointment for lightening pigmentation and eliminating scar hyperplasia is easy to generate skin reaction, therefore, the field expects to provide the medical radiation protection spray which has the activity of removing free radicals, lightening pigmentation and eliminating scar hyperplasia and does not generate skin reaction.
Disclosure of Invention
Aiming at the problems in the prior art, the invention provides a medical ray protection spray containing plant exosomes, which can effectively remove free radicals in the deep tissue, effectively repair cell damage and DNA damage and accelerate the repair of damaged skin.
The purpose of the invention is realized by the following technical scheme:
on one hand, the medical radiation protection spray containing the plant exosomes is provided, and consists of the following components: superoxide dismutase, rose exosome freeze-dried powder and purified water, wherein each 100ml of the rose exosome freeze-dried powder contains 0.05-0.1g of superoxide dismutase, 0.01-0.2g of rose exosome freeze-dried powder and the balance of purified water.
Preferably, the superoxide dismutase contained in 100ml contains 0.06-0.08 g.
Preferably, each 100ml contains 0.05-0.12g of rose exosome freeze-dried powder.
Preferably, the activity of superoxide dismutase is 3000U/mg.
In a second aspect, a medical radiation protection spray containing plant exosomes is provided, which consists of the following components: superoxide dismutase, rose exosome freeze-dried powder, sodium alginate and purified water; wherein, each 100ml contains 0.05-0.1g of superoxide dismutase, 0.01-0.2g of rose exosome freeze-dried powder, 0.1-0.2g of sodium alginate and the balance of purified water.
Preferably, the superoxide dismutase contained in 100ml contains 0.06-0.08 g.
Preferably, each 100ml contains 0.05-0.12g of rose exosome freeze-dried powder.
Preferably, each 100ml contains 0.15-0.18g of sodium alginate.
Preferably, the activity of superoxide dismutase is 3000U/mg.
The sodium alginate added in the second aspect of the invention can be used as an active stabilizer of superoxide dismutase and rose exosome freeze-dried powder, can avoid the inactivation of superoxide dismutase or rose exosome, and is beneficial to the long-term storage of the ray protection spray, and on the other hand, the sodium alginate has extremely strong water absorption performance, can keep the skin moist and is beneficial to the skin repair.
In a third aspect, a medical radiation protection spray containing plant exosomes is provided, which comprises the following components: superoxide dismutase, rose exosome freeze-dried powder, chitosan and purified water; wherein each 100ml contains superoxide dismutase 0.05-0.1g, flos Rosae Rugosae exosome lyophilized powder 0.01-0.2g, chitosan 0.1-0.2g, and the balance of purified water.
Preferably, the superoxide dismutase contained in 100ml contains 0.06-0.08 g.
Preferably, each 100ml contains 0.05-0.12g of rose exosome freeze-dried powder.
Preferably, the chitosan is 0.15-0.18g in each 100 ml.
Preferably, the chitosan is a pharmaceutical grade chitosan.
Preferably, the activity of superoxide dismutase is 3000U/mg.
The chitosan has good functions of moisture absorption, moisture preservation, conditioning, bacteriostasis and the like, can play a role of natural antibiotics to resist sensitivity and inflammation, quickly repair basal heat injury, quickly heal wound and repair epidermal barrier.
In a fourth aspect, a medical radiation protection spray containing plant exosomes is provided, which consists of the following components: superoxide dismutase, rose exosome freeze-dried powder, sodium alginate, chitosan and purified water; wherein, each 100ml contains 0.05-0.1g of superoxide dismutase, 0.01-0.2g of rose exosome freeze-dried powder, 0.1-0.2g of sodium alginate, 0.1-0.2g of chitosan and the balance of purified water.
Preferably, the superoxide dismutase contained in 100ml contains 0.06-0.08 g.
Preferably, each 100ml contains 0.05-0.12g of rose exosome freeze-dried powder.
Preferably, each 100ml contains 0.15-0.18g of sodium alginate.
Preferably, the chitosan is 0.15-0.18g in each 100 ml.
Preferably, the activity of superoxide dismutase is 3000U/mg.
The sodium alginate and the chitosan are added into the ray protection spray simultaneously as auxiliary components, so that the activities of superoxide dismutase and rose exosome can be protected, the effects of scavenging free radicals and repairing damaged cells are improved, the effective time of active ingredients of the medicine is prolonged, and the skin epidermis can be kept moist, thereby being beneficial to the rapid repair of the skin barrier.
In a fifth aspect, a medical radiation protection spray containing plant exosomes is provided, which consists of the following components: superoxide dismutase, rose exosome freeze-dried powder, sodium alginate, chitosan, vitamin C and purified water; wherein, each 100ml contains 0.05-0.1g of superoxide dismutase, 0.01-0.2g of rose exosome freeze-dried powder, 0.1-0.2g of sodium alginate, 0.1-0.2g of chitosan, 0.05-0.2g of vitamin C and the balance of purified water.
Preferably, the superoxide dismutase contained in 100ml contains 0.06-0.08 g.
Preferably, each 100ml contains 0.05-0.12g of rose exosome freeze-dried powder.
Preferably, each 100ml contains 0.15-0.18g of sodium alginate.
Preferably, the chitosan is 0.15-0.18g in each 100 ml.
Preferably, the vitamin C is 0.1-0.15g per 100 ml.
Preferably, the activity of superoxide dismutase is 3000U/mg.
The vitamin C has small molecular weight, is easier to permeate into the deep part of skin tissue, and has the effects of resisting oxidation, resisting free radicals and inhibiting the formation of tyrosinase, thereby achieving the effects of whitening and lightening spots.
In a sixth aspect, a medical radiation protection spray containing plant exosomes is provided, which consists of the following components: superoxide dismutase, rose exosome freeze-dried powder, sodium alginate, chitosan, vitamin C, vitamin E acetate and purified water; wherein, each 100ml contains 0.05-0.1g of superoxide dismutase, 0.01-0.2g of rose exosome freeze-dried powder, 0.1-0.2g of sodium alginate, 0.1-0.2g of chitosan, 0.05-0.2g of vitamin C, 0.1-0.4g of vitamin E acetate and the balance of purified water.
Preferably, the superoxide dismutase contained in 100ml contains 0.06-0.08 g.
Preferably, each 100ml contains 0.05-0.12g of rose exosome freeze-dried powder.
Preferably, each 100ml contains 0.15-0.18g of sodium alginate.
Preferably, the chitosan is 0.15-0.18g in each 100 ml.
Preferably, the vitamin C is 0.1-0.15g per 100 ml.
Preferably, the vitamin E acetate is 0.25-0.35g per 100 ml.
Preferably, the activity of superoxide dismutase is 3000U/mg.
The vitamin E acetate is an oil-soluble natural substance, is a good nutritional moisturizer for skin, has good effects of resisting oxidation, moisturizing and maintaining connective tissues and protecting the skin from being damaged by ultraviolet rays, can effectively keep the skin moisture by being used in cooperation with vitamin C, promotes wound healing, prevents inflammation, prevents rough and chapped skin, improves black spots, avoids pigment deposition and can prevent photoreaction.
In a seventh aspect, a medical radiation protection spray containing plant exosomes is provided, which consists of the following components: superoxide dismutase, rose exosome freeze-dried powder, sodium alginate, chitosan, mannitol, potassium sorbate and purified water; wherein, each 100ml contains 0.05-0.1g of superoxide dismutase, 0.01-0.2g of rose exosome freeze-dried powder, 0.1-0.2g of sodium alginate, 0.1-0.2g of chitosan, 0.2-0.4g of mannitol, 0.1-0.4g of potassium sorbate and the balance of purified water.
Preferably, the superoxide dismutase contained in 100ml contains 0.06-0.08 g.
Preferably, each 100ml contains 0.05-0.12g of rose exosome freeze-dried powder.
Preferably, each 100ml contains 0.15-0.18g of sodium alginate.
Preferably, the chitosan is 0.15-0.18g in each 100 ml.
Preferably, mannitol is contained in an amount of 0.3-0.35g per 100 ml.
Preferably, each 100ml contains 0.25-0.35g of potassium sorbate.
Preferably, the activity of superoxide dismutase is 3000U/mg.
The mannitol can remove peroxynitrite anion of skin tissue, thereby avoiding pigmentation, has a certain inhibition effect on skin allergy, can inhibit skin photodamage and photoaging, and has moisturizing and skin conditioning functions.
In an eighth aspect, a medical radiation protection spray containing plant exosomes is provided, which comprises the following components: superoxide dismutase, rose exosome freeze-dried powder, sodium alginate, chitosan, mannitol, glycerol, potassium sorbate and purified water; wherein, each 100ml contains 0.05-0.1g of superoxide dismutase, 0.01-0.2g of rose exosome freeze-dried powder, 0.1-0.2g of sodium alginate, 0.1-0.2g of chitosan, 0.2-0.4g of mannitol, 0.1-1g of glycerol, 0.1-0.4g of potassium sorbate and the balance of purified water.
Preferably, the superoxide dismutase contained in 100ml contains 0.06-0.08 g.
Preferably, each 100ml contains 0.05-0.12g of rose exosome freeze-dried powder.
Preferably, each 100ml contains 0.15-0.18g of sodium alginate.
Preferably, the chitosan is 0.15-0.18g in each 100 ml.
Preferably, mannitol is contained in an amount of 0.3-0.35g per 100 ml.
Preferably, glycerol is contained in an amount of 0.5 to 0.8g per 100 ml.
Preferably, each 100ml contains 0.25-0.35g of potassium sorbate.
Preferably, the activity of superoxide dismutase is 3000U/mg.
The glycerol can fill intercellular substance and absorb appropriate amount of water to maintain stability of skin cells.
In a ninth aspect, the invention provides a preparation method of the rose exosome freeze-dried powder, which comprises the following steps:
(1) pouring fresh rose petals into a juicer, adding sterilized PBS, juicing and homogenizing, centrifuging at 3500g and 4 ℃ for 18min, and removing larger residues; centrifuging the yellow transparent solution in the middle layer at 12000g at 4 deg.C for 40-70 min; taking the supernatant, ultracentrifuging at 4 ℃ for 60 min at 120000g, then using 1ml sterile PBS to resuspend the precipitate, and then ultracentrifuging at 4 ℃ for 80 min at 120000 g; after centrifugation, the precipitate was resuspended in 2ml sterile PBS, at which time the rose exosome extract was obtained.
(2) Freezing the obtained rose exosome extract at-35-40 ℃ for 0.5-1.5h until the central temperature of the material is below-25 ℃, heating the material by a heating plate, raising the temperature of the heating plate to 93 ℃ within 0.5h and maintaining for 4-6h, lowering the temperature of the heating plate to 88 ℃ within 0.5h and maintaining for 4-6h, lowering the temperature of the heating plate to 75 ℃ within 0.5h and maintaining for 4-6h, lowering the temperature of the heating plate to 65 ℃ within 0.5h and maintaining for 4-6h until the temperature of the material is not changed, and obtaining the rose exosome freeze-dried powder.
In a tenth aspect, the invention provides application of rose exosome freeze-dried powder in preparation of a medical ray protection spray.
The superoxide dismutase, the sodium alginate, the chitosan, the mannitol, the glycerol and the potassium sorbate are obtained by purchasing through conventional channels.
Compared with the prior art, the invention has the beneficial effects that:
the medical ray protection spray containing the plant exosomes consists of superoxide dismutase, rose exosome freeze-dried powder and purified water, wherein the superoxide dismutase is superoxide radical (O)-2) The invention creatively adds the rose exosome into the components, the rose exosome carries special cell factors of plants and various protein signals, and can target and decompose functional substances and be absorbed by skin cells when contacting with damaged skin, and the rose exosome can rapidly break through the skin barrier and permeate into the deep part of the skin tissue to clear free radicals in the deep part of the skin tissue, neutralize, reduce and block active oxygen chain-forming chain when contacting with the damaged skin, and the rose exosome can rapidly break through the skin barrier and permeate into the deep part of the skin tissue to clear free radicals in the deep part of the skin tissue, reduce and block active oxygen chain-forming chainCarrying out a reaction of the formula (I); on the other hand, the cell factors carried by the rose exosomes can repair damaged cells and damaged DNA from the root, activate the activity of skin cells, resist bacteria and diminish inflammation, achieve the function of quick repair, particularly have better treatment effect on skin with ulcer, and the superoxide dismutase and the rose exosomes are matched with each other, so that superficial and deep free radicals of skin tissues can be quickly and effectively eliminated, the damaged skin can be quickly repaired, anaphylaxis cannot be generated, and other side effects cannot be caused.
DETAILED DESCRIPTION OF EMBODIMENT (S) OF INVENTION
Example 1
The embodiment provides a medical radiation protection spray containing plant exosomes, which consists of the following components: the rose superoxide dismutase composition comprises superoxide dismutase, rose exosome freeze-dried powder and purified water, wherein each 100ml of the rose exosome freeze-dried powder comprises 0.05g of superoxide dismutase, 0.2g of rose exosome freeze-dried powder and the balance of purified water.
In some embodiments, 0.06g, 0.07g, 0.08g, 0.09g, or 0.1g superoxide dismutase is contained per 100 ml.
In some embodiments, the rose exosome lyophilized powder is contained in 100ml at 0.01g, 0.02g, 0.03g, 0.04g, 0.05g, 0.06g, 0.07g, 0.08g, 0.09g, 0.1g, 0.11g, 0.12g, 0.13g, 0.14g, 0.15g, 0.16g, 0.17g, 0.18g or 0.19 g.
The activity of the superoxide dismutase in the embodiment is 2000-4000U/mg.
The medical ray protection spray containing the plant exosomes has strong oxidation resistance, can thoroughly remove free radicals in deep tissues, can quickly repair damaged skin, can prevent dermatitis, and can effectively relieve dermatitis symptoms.
Example 2
The embodiment provides a medical radiation protection spray containing plant exosomes, which consists of the following components: superoxide dismutase, rose exosome freeze-dried powder, sodium alginate and purified water; wherein, each 100ml contains 0.1g of superoxide dismutase, 0.01g of rose exosome freeze-dried powder, 0.1g of sodium alginate and the balance of purified water.
In some embodiments, 0.05g, 0.06g, 0.07g, 0.08g, or 0.09g of superoxide dismutase is contained per 100 ml.
In some embodiments, the rose exosome lyophilized powder is contained in 100ml at 0.01g, 0.02g, 0.03g, 0.04g, 0.05g, 0.06g, 0.07g, 0.08g, 0.09g, 0.11g, 0.12g, 0.13g, 0.14g, 0.15g, 0.16g, 0.17g, 0.18g, 0.19g or 0.20 g.
In some embodiments, sodium alginate is present in an amount of 0.11g, 0.12g, 0.13g, 0.14g, 0.15g, 0.16g, 0.17g, 0.18g, 0.19g or 0.20g per 100 ml.
The activity of the superoxide dismutase in the embodiment is 2000-4000U/mg. Sodium alginate added in the ray protection spray can be used as an active stabilizer of superoxide dismutase and rose exosome freeze-dried powder, inactivation of superoxide dismutase or rose exosome can be avoided, long-term storage of the ray protection spray is facilitated, and on the other hand, the sodium alginate has extremely strong water absorption performance, can keep skin moist, and is beneficial to skin repair.
Example 3
The embodiment provides a medical radiation protection spray containing plant exosomes, which consists of the following components: superoxide dismutase, rose exosome freeze-dried powder, chitosan and purified water; wherein, each 100ml contains 0.08g of superoxide dismutase, 0.15g of rose exosome freeze-dried powder, 0.1g of chitosan and the balance of purified water.
In some embodiments, 0.05g, 0.06g, 0.07g, 0.09g, or 0.1g superoxide dismutase is present per 100 ml.
In some embodiments, 0.01g, 0.02g, 0.03g, 0.04g, 0.05g, 0.06g, 0.07g, 0.08g, 0.09g, 0.10g, 0.11g, 0.12g, 0.13g, 0.14g, 0.16g, 0.17g, 0.18g, 0.19g, or 0.20g of the lyophilized rose exosome powder is contained per 100 ml.
In some embodiments, each 100ml contains chitosan at 0.11g, 0.12g, 0.13g, 0.14g, 0.16g, 0.17g, 0.18g, 0.19g, or 0.20 g.
In some embodiments, the chitosan is a pharmaceutical grade chitosan.
The activity of the superoxide dismutase in the embodiment is 2000-4000U/mg. The chitosan has good functions of moisture absorption, moisture preservation, conditioning, bacteriostasis and the like, can play a role of natural antibiotics to resist sensitivity and inflammation, quickly repair basal heat injury, quickly heal wound and repair epidermal barrier.
Example 4
The embodiment provides a medical radiation protection spray containing plant exosomes, which consists of the following components: superoxide dismutase, rose exosome freeze-dried powder, sodium alginate, chitosan and purified water; wherein, each 100ml contains 0.07g of superoxide dismutase, 0.2g of rose exosome freeze-dried powder, 0.2g of sodium alginate, 0.2g of chitosan and the balance of purified water.
In some embodiments, 0.05g, 0.06g, 0.08g, 0.09g, or 0.1g superoxide dismutase is present per 100 ml.
In some embodiments, the rose exosome lyophilized powder is contained in 100ml at 0.01g, 0.02g, 0.03g, 0.04g, 0.05g, 0.06g, 0.07g, 0.08g, 0.09g, 0.10g, 0.11g, 0.12g, 0.13g, 0.14g, 0.15g, 0.16g, 0.17g, 0.18g or 0.19 g.
In some embodiments, sodium alginate is present in an amount of 0.1g, 0.11g, 0.12g, 0.13g, 0.14g, 0.15g, 0.16g, 0.17g, 0.18g or 0.19g per 100 ml.
In some embodiments, chitosan is present at 0.1g, 0.11g, 0.12g, 0.13g, 0.14g, 0.15g, 0.16g, 0.17g, 0.18g, or 0.19g per 100 ml.
In some embodiments, the chitosan is a pharmaceutical grade chitosan.
The activity of the superoxide dismutase in the embodiment is 2000-4000U/mg. The sodium alginate and the chitosan are added into the ray protection spray simultaneously as auxiliary components, so that the activities of superoxide dismutase and rose exosome can be protected, the effects of scavenging free radicals and repairing damaged cells are improved, the effective time of active ingredients of the medicine is prolonged, and the skin epidermis can be kept moist, thereby being beneficial to the rapid repair of the skin barrier. The sodium alginate and the chitosan can synergistically play the roles of protecting active ingredients and moisturizing skin, and the effect of the active ingredients is maximized.
Example 5
The embodiment provides a medical radiation protection spray containing plant exosomes, which consists of the following components: superoxide dismutase, rose exosome freeze-dried powder, sodium alginate, chitosan, vitamin C and purified water; wherein, each 100ml contains 0.06g of superoxide dismutase, 0.1g of rose exosome freeze-dried powder, 0.1g of sodium alginate, 0.2g of chitosan, 0.05 of vitamin C and the balance of purified water.
In some embodiments, 0.05g, 0.07g, 0.09g, or 0.1g superoxide dismutase is contained per 100 ml.
In some embodiments, the rose exosome lyophilized powder is contained in 100ml at 0.01g, 0.02g, 0.03g, 0.04g, 0.05g, 0.06g, 0.07g, 0.08g, 0.09g, 0.11g, 0.12g, 0.13g, 0.14g, 0.15g, 0.16g, 0.17g, 0.18g, 0.19g or 0.20 g.
In some embodiments, sodium alginate is present in an amount of 0.11g, 0.12g, 0.13g, 0.14g, 0.16g, 0.17g, 0.18g, 0.19g or 0.20g per 100 ml.
In some embodiments, each 100ml contains chitosan at 0.1g, 0.11g, 0.12g, 0.13g, 0.14g, 0.16g, 0.17g, 0.18g, or 0.19 g.
In some embodiments, the chitosan is a pharmaceutical grade chitosan.
In some embodiments, vitamin C is present at 0.06, 0.07, 0.08, 0.09, 0.1, 0.11g, 0.12g, 0.13g, 0.14g, 0.16g, 0.17g, 0.18g, or 0.19g per 100 ml.
The activity of the superoxide dismutase in the embodiment is 2000-4000U/mg. The vitamin C has small molecular weight, is easier to permeate into the deep part of skin tissue, and has the effects of resisting oxidation, resisting free radicals and inhibiting the formation of tyrosinase, thereby achieving the effects of whitening and lightening spots.
Example 6
The embodiment provides a medical radiation protection spray containing plant exosomes, which consists of the following components: superoxide dismutase, rose exosome freeze-dried powder, sodium alginate, chitosan, vitamin C, vitamin E acetate and purified water; wherein, each 100ml contains 0.09g of superoxide dismutase, 0.18g of rose exosome freeze-dried powder, 0.15g of sodium alginate, 0.15g of chitosan, 0.2g of vitamin C, 0.1g of vitamin E acetate and the balance of purified water.
In some embodiments, 0.05g, 0.06g, 0.07g, 0.08g, or 0.1g superoxide dismutase is present per 100 ml.
In some embodiments, 0.01g, 0.02g, 0.03g, 0.04g, 0.05g, 0.06g, 0.07g, 0.08g, 0.09g, 0.11g, 0.12g, 0.13g, 0.14g, 0.15g, 0.16g, 0.17g, 0.19g, or 0.20g of the rose exosome lyophilized powder is contained per 100 ml.
In some embodiments, sodium alginate is present in an amount of 0.1g, 0.11g, 0.12g, 0.13g, 0.14g, 0.16g, 0.17g, 0.18g, 0.19g or 0.20g per 100 ml.
In some embodiments, chitosan is present at 0.1g, 0.11g, 0.12g, 0.13g, 0.14g, 0.16g, 0.17g, 0.18g, 0.19g, or 0.20g per 100 ml.
In some embodiments, the chitosan is a pharmaceutical grade chitosan.
In some embodiments, vitamin C is present in an amount of 0.05, 0.06, 0.07, 0.08, 0.09, 0.1g, 0.11g, 0.12g, 0.13g, 0.14g, 0.16g, 0.17g, 0.18g, or 0.19g per 100 ml.
In some embodiments, the vitamin E acetate comprises, per 100ml, 0.11g, 0.12g, 0.13g, 0.14g, 0.16g, 0.17g, 0.18g, 0.19g, 0.20g, 0.21g, 0.22g, 0.23g, 0.24g, 0.25g, 0.26g, 0.27g, 0.28g, 0.29g, 0.30g, 0.31g, 0.32g, 0.33g, 0.34g, 0.35g, 0.36g, 0.37g, 0.38g, 0.39g, or 0.40g,
The activity of the superoxide dismutase in the embodiment is 2000-4000U/mg. The vitamin E acetate is an oil-soluble natural substance, is a good nutritional moisturizer for skin, has good effects of resisting oxidation, moisturizing and maintaining connective tissues and protecting the skin from being damaged by ultraviolet rays, can effectively keep the skin moisture by being used in cooperation with vitamin C, promotes wound healing, prevents inflammation, prevents rough and chapped skin, improves black spots, avoids pigment deposition and can prevent photoreaction.
Example 7
The embodiment provides a medical radiation protection spray containing plant exosomes, which consists of the following components: superoxide dismutase, rose exosome freeze-dried powder, sodium alginate, chitosan, mannitol, potassium sorbate and purified water; wherein, each 100ml contains 0.09g of superoxide dismutase, 0.05g of rose exosome freeze-dried powder, 0.14g of sodium alginate, 0.16g of chitosan, 0.3g of mannitol, 0.1g of potassium sorbate and the balance of purified water.
In some embodiments, 0.05g, 0.06g, 0.07g, 0.08g, or 0.1g superoxide dismutase is present per 100 ml.
In some embodiments, 0.01g, 0.02g, 0.03g, 0.04g, 0.06g, 0.07g, 0.08g, 0.09g, 0.11g, 0.12g, 0.13g, 0.14g, 0.15g, 0.16g, 0.17g, 0.18g, 0.19g, or 0.20g of the rose exosome lyophilized powder is contained per 100 ml.
In some embodiments, sodium alginate is present in an amount of 0.1g, 0.11g, 0.12g, 0.13g, 0.15g, 0.16g, 0.17g, 0.18g, 0.19g or 0.20g per 100 ml.
In some embodiments, chitosan is present at 0.1g, 0.11g, 0.12g, 0.13g, 0.14g, 0.15g, 0.17g, 0.18g, 0.19g, or 0.20g per 100 ml.
In some embodiments, the chitosan is a pharmaceutical grade chitosan.
In some embodiments, mannitol is present in an amount of 0.2g, 0.21g, 0.22g, 0.23g, 0.24g, 0.25g, 0.26g, 0.27g, 0.28g, 0.29g, 0.31g, 0.32g, 0.33g, 0.34g, 0.35g, 0.36g, 0.37g, 0.38g, 0.39g, or 0.40g per 100 ml.
In some embodiments, 0.11g, 0.12g, 0.13g, 0.14g, 0.16g, 0.17g, 0.18g, 0.19g, 0.20g, 0.21g, 0.22g, 0.23g, 0.24g, 0.25g, 0.26g, 0.27g, 0.28g, 0.29g, 0.30g, 0.31g, 0.32g, 0.33g, 0.34g, 0.35g, 0.36g, 0.37g, 0.38g, 0.39g, or 0.40g of potassium sorbate is contained per 100 ml.
The activity of the superoxide dismutase in the embodiment is 2000-4000U/mg.
The mannitol can remove peroxynitrite anion of skin tissue, thereby avoiding pigmentation, has a certain inhibition effect on skin allergy, can inhibit skin photodamage and photoaging, and has moisturizing and skin conditioning functions.
Example 8
The embodiment provides a medical radiation protection spray containing plant exosomes, which consists of the following components: superoxide dismutase, rose exosome freeze-dried powder, sodium alginate, chitosan, mannitol, glycerol, potassium sorbate and purified water; wherein, each 100ml contains 0.06g of superoxide dismutase, 0.05g of rose exosome freeze-dried powder, 0.17g of sodium alginate, 0.17g of chitosan, 0.2g of mannitol, 1g of glycerol, 0.4g of potassium sorbate and the balance of purified water.
In some embodiments, 0.05g, 0.07g, 0.08g, 0.09g, or 0.1g superoxide dismutase is present per 100 ml.
In some embodiments, 0.01g, 0.02g, 0.03g, 0.04g, 0.06g, 0.07g, 0.08g, 0.09g, 0.11g, 0.12g, 0.13g, 0.14g, 0.15g, 0.16g, 0.17g, 0.18g, 0.19g, or 0.20g of the rose exosome lyophilized powder is contained per 100 ml.
In some embodiments, sodium alginate is present in an amount of 0.1g, 0.11g, 0.12g, 0.13g, 0.14g, 0.16g, 0.18g, 0.19g or 0.20g per 100 ml.
In some embodiments, chitosan is present at 0.1g, 0.11g, 0.12g, 0.13g, 0.14g, 0.15g, 0.16g, 0.18g, 0.19g, or 0.20g per 100 ml.
In some embodiments, the chitosan is a pharmaceutical grade chitosan.
In some embodiments, mannitol is present in 100ml at 0.21g, 0.22g, 0.23g, 0.24g, 0.25g, 0.26g, 0.27g, 0.28g, 0.29g, 0.30g, 0.31g, 0.32g, 0.33g, 0.34g, 0.35g, 0.36g, 0.37g, 0.38g, 0.39g, or 0.40 g;
in some embodiments, glycerol is present at 0.5g, 0.55g, 0.6g, 0.65g, 0.7g, 0.75 g, or 0.8g per 100 ml;
in some embodiments, 0.1g, 0.11g, 0.12g, 0.13g, 0.14g, 0.16g, 0.17g, 0.18g, 0.19g, 0.20g, 0.21g, 0.22g, 0.23g, 0.24g, 0.25g, 0.26g, 0.27g, 0.28g, 0.29g, 0.30g, 0.31g, 0.32g, 0.33g, 0.34g, 0.35g, 0.36g, 0.37g, 0.38g, or 0.39g of potassium sorbate is contained per 100 ml.
The activity of the superoxide dismutase in the embodiment is 2000-4000U/mg.
Effect verification test:
(1) study of product effectiveness
A. Method of producing a composite material
165 SD rats with unlimited male and female bodies and a body weight of 220g +/-20 g are randomly divided into 15 groups of an experimental group 1, an experimental group 2, an experimental group 3, an experimental group 4, an experimental group 5, an experimental group 6, an experimental group 7, an experimental group 8, a control group, a model group and a blank group. Before radiotherapy, SD rats are anesthetized in the abdominal cavity by 1% sodium pentobarbital (35 mg/kg), and the skin on the back of the rats is depilated by 8% sodium sulfide solution (or depilatory cream), wherein the area is about 3cm multiplied by 3 cm. High-energy X rays emitted by a 6Mev linear accelerator are used for locally irradiating the skin at the depilatory position at a single time, the distance between a radioactive source and the skin is 80cm, the non-irradiated part is covered by a lead plate, the irradiation dose rate is 400cGy/min, and the irradiation dose is 40 Gy. Sending the irradiated animal back to the animal room for uniform breeding. In test groups 1-8, radiation protection sprays corresponding to embodiments 1-8 of the invention were sprayed to the irradiated parts every day from 1 day before radiotherapy to 21 days after radiotherapy, 3 times a day, 2 sprays each time; spraying a product corresponding to patent CN201810683369.5 in an equal amount in a control group, and spraying physiological saline in an equal amount in a model group; the blank groups were not processed. The preventive and therapeutic effects were evaluated on the basis of the classification criteria of acute radiodermatitis (0 degree: no change; i degree: follicular, mild erythema, dry desquamation, decreased sweating; ii degree: marked erythema, macular hygropdermatitis, moderate edema; iii degree: fusional hygropdermatitis, depressed edema; iv degree: necrosis, ulcer, hemorrhage).
B. Results
The results of the tests are shown in the following table. Statistical analysis was performed using the X2 test.
TABLE 1 number of cases of radiodermatitis in animals at different times after radiotherapy
As can be seen from the results in Table 1, the experimental groups 1 to 8 have better prevention effect on the radiodermatitis 7 to 14 days after the radiation; 14-28 days after radiation, the experimental groups 1-8 have better effect of relieving the radiodermatitis, and particularly can effectively reduce the incidence rate of the radiodermatitis with I-IV degrees. It is demonstrated that the radioprotective sprays of inventive patent examples 1-8 are superior to similar products.
(2) Study on moisture Retention
A. Method of producing a composite material
100 subjects, randomized into 10 groups of 10 persons each. Before the experiment, a skin moisture test pen is adopted to detect the forearm skin moisture of each subject; then, the subjects in the experimental groups 1 to 8 are respectively sprayed with the ray protection spray of the examples 1 to 8 correspondingly, the subjects in the control group are sprayed with the product corresponding to the patent CN201810683369.5, the blank group is sprayed with purified water, and the moisture content of the skin of the same part of the subjects is detected after 5min, 10min, 20min and 30min after the spraying. Skin moisture increment = skin moisture content after use-skin moisture content before use.
B. Results
TABLE 2 skin moisture increment (%) (before and after use by test persons)
| Group of | Experimental group 1 | Experimental group 2 | Experimental group 3 | Experimental group 3 | Experimental group 5 | Experimental group 6 | Experimental group 7 | Experimental group 8 | Control group | Blank group |
| Before use | 38.2±1.4 | 37.9±1.6 | 38.1±1.4 | 37.9±1.6 | 38.2±1.2 | 38.3±1.5 | 38.2±1.4 | 38.5±1.2 | 38.5±2.0 | 38.8±2.7 |
| 5min | 47.4±1.5 | 47.1±1.5 | 48.4±1.5 | 49.7±1.5 | 48.6±1.5 | 48.9±1.5 | 49.4±1.5 | 49.1±1.5 | 43.3±2.1 | 42.4±3.4 |
| 10min | 55.5±2.8 | 55.3±2.5 | 56.5±2.8 | 58.3±2.5 | 57.5±2.8 | 59.3±2.5 | 58.5±2.8 | 58.3±2.5 | 47.3±1.8 | 39.4±1.6 |
| 20min | 45.3±3.0 | 45.7±2.9 | 46.3±3.0 | 49.7±2.9 | 48.3±3.0 | 45.7±2.9 | 47.3±3.0 | 48.7±2.9 | 42.2±1.6 | 38.6±2.2 |
| 30min | 44.5±1.6 | 44.1±2.1 | 45.5±1.6 | 47.1±2.1 | 46.5±1.6 | 46.1±2.1 | 45.5±1.6 | 47.1±2.1 | 39.7±1.8 | 37.5±1.7 |
As can be seen from the results in Table 2, the experimental groups 1 to 8 had moisturizing ability > control group > purified water.
The above description is only an embodiment of the present application, but the scope of the present application is not limited thereto, and any changes or substitutions within the technical scope of the present disclosure should be covered by the scope of the present application. Therefore, the protection scope of the present application shall be subject to the protection scope of the claims.
Claims (8)
1. The medical ray protection spray containing the plant exosomes is characterized by comprising the following components: superoxide dismutase, rose exosome freeze-dried powder and purified water, wherein each 100ml of the rose exosome freeze-dried powder contains 0.05-0.1g of superoxide dismutase, 0.01-0.2g of rose exosome freeze-dried powder and the balance of purified water.
2. The medical ray protection spray containing the plant exosomes is characterized by comprising the following components: superoxide dismutase, rose exosome freeze-dried powder, sodium alginate and purified water; wherein, each 100ml contains 0.05-0.1g of superoxide dismutase, 0.01-0.2g of rose exosome freeze-dried powder, 0.1-0.2g of sodium alginate and the balance of purified water.
3. The medical ray protection spray containing the plant exosomes is characterized by comprising the following components: superoxide dismutase, rose exosome freeze-dried powder, chitosan and purified water; wherein each 100ml contains superoxide dismutase 0.05-0.1g, flos Rosae Rugosae exosome lyophilized powder 0.01-0.2g, chitosan 0.1-0.2g, and the balance of purified water.
4. The medical ray protection spray containing the plant exosomes is characterized by comprising the following components: superoxide dismutase, rose exosome freeze-dried powder, sodium alginate, chitosan and purified water; wherein, each 100ml contains 0.05-0.1g of superoxide dismutase, 0.01-0.2g of rose exosome freeze-dried powder, 0.1-0.2g of sodium alginate, 0.1-0.2g of chitosan and the balance of purified water.
5. The medical ray protection spray containing the plant exosomes is characterized by comprising the following components: superoxide dismutase, rose exosome freeze-dried powder, sodium alginate, chitosan, vitamin C and purified water; wherein, each 100ml contains 0.05-0.1g of superoxide dismutase, 0.01-0.2g of rose exosome freeze-dried powder, 0.1-0.2g of sodium alginate, 0.1-0.2g of chitosan, 0.05-0.2g of vitamin C and the balance of purified water.
6. The medical ray protection spray containing the plant exosomes is characterized by comprising the following components: superoxide dismutase, rose exosome freeze-dried powder, sodium alginate, chitosan, vitamin C, vitamin E acetate and purified water; wherein, each 100ml contains 0.05-0.1g of superoxide dismutase, 0.01-0.2g of rose exosome freeze-dried powder, 0.1-0.2g of sodium alginate, 0.1-0.2g of chitosan, 0.05-0.2g of vitamin C, 0.1-0.4g of vitamin E acetate and the balance of purified water.
7. The medical ray protection spray containing the plant exosomes is characterized by comprising the following components: superoxide dismutase, rose exosome freeze-dried powder, sodium alginate, chitosan, mannitol, potassium sorbate and purified water; wherein, each 100ml contains 0.05-0.1g of superoxide dismutase, 0.01-0.2g of rose exosome freeze-dried powder, 0.1-0.2g of sodium alginate, 0.1-0.2g of chitosan, 0.2-0.4g of mannitol, 0.1-0.4g of potassium sorbate and the balance of purified water.
8. The medical ray protection spray containing the plant exosomes is characterized by comprising the following components: superoxide dismutase, rose exosome freeze-dried powder, sodium alginate, chitosan, mannitol, glycerol, potassium sorbate and purified water; wherein, each 100ml contains 0.05-0.1g of superoxide dismutase, 0.01-0.2g of rose exosome freeze-dried powder, 0.1-0.2g of sodium alginate, 0.1-0.2g of chitosan, 0.2-0.4g of mannitol, 0.1-1g of glycerol, 0.1-0.4g of potassium sorbate and the balance of purified water.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202011053392.XA CN112220914A (en) | 2020-09-29 | 2020-09-29 | Medical ray protection spray containing plant exosomes |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202011053392.XA CN112220914A (en) | 2020-09-29 | 2020-09-29 | Medical ray protection spray containing plant exosomes |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN112220914A true CN112220914A (en) | 2021-01-15 |
Family
ID=74119560
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202011053392.XA Pending CN112220914A (en) | 2020-09-29 | 2020-09-29 | Medical ray protection spray containing plant exosomes |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN112220914A (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN114344360A (en) * | 2022-01-07 | 2022-04-15 | 阿谷巴(杭州)生物科技发展有限公司 | Exosome compound preparation for skin photodamage repair and preparation method thereof |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103751770A (en) * | 2014-02-11 | 2014-04-30 | 苏州东泉生物科技有限公司 | Medical ray protection washing agent |
| CN105920590A (en) * | 2016-04-28 | 2016-09-07 | 福建省乐华医药科技有限公司 | Medical x-ray protection spray |
| CN109568414A (en) * | 2018-12-18 | 2019-04-05 | 王 | The method and application of rose Essence and excretion body are extracted from rose |
| CN110652581A (en) * | 2018-06-28 | 2020-01-07 | 陕西佰傲再生医学有限公司 | Medical ray protection solution with moisturizing and itching relieving effects and preparation method thereof |
-
2020
- 2020-09-29 CN CN202011053392.XA patent/CN112220914A/en active Pending
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103751770A (en) * | 2014-02-11 | 2014-04-30 | 苏州东泉生物科技有限公司 | Medical ray protection washing agent |
| CN105920590A (en) * | 2016-04-28 | 2016-09-07 | 福建省乐华医药科技有限公司 | Medical x-ray protection spray |
| CN110652581A (en) * | 2018-06-28 | 2020-01-07 | 陕西佰傲再生医学有限公司 | Medical ray protection solution with moisturizing and itching relieving effects and preparation method thereof |
| CN109568414A (en) * | 2018-12-18 | 2019-04-05 | 王 | The method and application of rose Essence and excretion body are extracted from rose |
Non-Patent Citations (1)
| Title |
|---|
| 奚廷斐等: "海洋生物医用材料临床应用", 上海科学技术出版社, pages: 252 - 254 * |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN114344360A (en) * | 2022-01-07 | 2022-04-15 | 阿谷巴(杭州)生物科技发展有限公司 | Exosome compound preparation for skin photodamage repair and preparation method thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP2278986B1 (en) | A product for topical administration | |
| US5266318A (en) | Skin therapeutic mixture containing cold-processsed aloe vera extract, with yellow sap and aloin removed | |
| US8303985B2 (en) | Skin treatment compositions containing copper-pigment complexes | |
| CN104622897A (en) | Skin moisturizer for treating skin disease and preparation method of skin moisturizer | |
| CN106309156A (en) | Ferulic acid acne fading solution and preparation method thereof | |
| CN112220914A (en) | Medical ray protection spray containing plant exosomes | |
| CN114848565A (en) | Acne removing composition, acne removing gel and preparation method of acne removing gel | |
| CN105920589A (en) | Medical ray protection spray and preparation process thereof | |
| CN110652581A (en) | Medical ray protection solution with moisturizing and itching relieving effects and preparation method thereof | |
| US9375462B1 (en) | Composition for healing skin | |
| CN113876883B (en) | Novel medicament for resisting ultraviolet damage in battle-specific environment and preparation method thereof | |
| US9867874B1 (en) | Composition for regulating immunomodulation of skin | |
| CN112206316B (en) | Medical ray protective agent and preparation method thereof | |
| KR101374537B1 (en) | Pharmaceutical Composition for Burn Treatment Using Gombo-Baechu | |
| Devi | Cosmeceutical applications of aloe gel | |
| CN109431824B (en) | Antibacterial deodorizing gel and application thereof | |
| CN110393772A (en) | A kind of pharmaceutical composition and preparation method promoting radiotherapy patient skin wound healing | |
| CN106266453A (en) | A kind of composition for external application and application thereof | |
| CN107982300B (en) | Spray and preparation method and application thereof | |
| CN110063992A (en) | Burn and scald medication and preparation method thereof | |
| KR101711004B1 (en) | Kit comprising anti-trouble composition and portable apparatus having a heat source united with a light irradiation and the method for improving skin beauty using the same | |
| US10434151B1 (en) | Method for treating and maintaining skin | |
| CN105267951B (en) | A kind of nanometer silver antimicrobial ionized water wound care composition | |
| EP3355900B1 (en) | A gynura procumbens oil extract for the treatment of several dermatological diseases and its process thereof | |
| CN107050298A (en) | A kind of Chinese medicine paste formulation and preparation method for treating burn and scald skin damaged |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination |